Formycon Reports Initiation of P-I Trial for FYB202 (biosimilar, ustekinumab)

Formycon Reports Initiation of P-I Trial for FYB202 (biosimilar, ustekinumab)
  • The P-I study involves assessing of FYB202 vs Stelara in patients evaluating the PK, safety, and tolerability while their dosing has been started last week
  • Bioeq GmbH to sponsor the trial and will take care of study design and clinical operation FYB202 is developed in a joint venture between Aristo Pharma GmbH and Formycon AG
  • FYB202 is a mAb targeting cytokines interleukin-12 and interleukin-23 used for the treatment of several different serious inflammatory diseases, such as moderate to severe psoriasis including UC, Crohn’s disease and psoriatic arthritis  

Click here to­ read full press release/ article | Ref: Formycon | Image: Behance